AlzBiomarker
Control vs Alzheimer's Disease: Aβ42 (CSF)
Meta-analysis of more than 200 comparisons showed that the level of Aβ42 in the cerebrospinal fluid of control subjects is nearly double that in the CSF of people with Alzheimer's disease (effect size = 1.818, p <0.0001). The decrease in Aβ42 in the CSF of AD patients is thought to reflect the deposition of the peptide into amyloid plaques in the brain.
Loading data...